MaaT Pharma has received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) for MaaT013 (Xervyteg) following re-examination for its conditional marketing authorisation application. The committee’s concerns relate primarily to the attribution of clinical benefit and safety in the absence of a… Read More
An engineered gut bacteria therapy could be an alternative to foecal microbiota transplants (FMT), researchers say. Results from a Phase Ib clinical study demonstrate comparable safety and efficacy between stool-based FMT and manufactured live biotherapeutic product (LBP). Scientists at the Icahn School of Medicine at Mount Sinai, New York developed the… Read More
Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer. … Read More
Jeff Fischer, MBA, president of Longhorn Vaccines and Diagnostics, examines how upstream activations in the gut microbiome can be utilised to tackle therapeutic targets. The microbiome has become a catch‑all explanation for everything from obesity to depression, but it can obscure a simpler and more actionable idea: that living microbes matter, but what they shed matters too. Every… Read More
The first patient has been randomised in a Phase II trial evaluating an oral microbiome therapy in combination with Cemiplimab to treat patients with advanced non-small cell lung cancer (NSCLC). Maat033, an oral microbiome developed by biotechnology company MaaT Pharma, is being studied as a treatment in combination with Cemiplimab in enhancing disease… Read More
Biopharmaceutical company EnteroBiotix has announced positive final results from its TrIuMPH clinical trial, which is evaluating the company’s full-spectrum microbiome therapeutic for patients with irritable bowel syndrome with constipation (IBS-C) with constipation or diarrhoea (IBS-D). The Phase IIa clinical trial included 122 UK patients and results show that EBX-102-02 demonstrated clinically meaningful improvements in the IBS symptom severity score (IBS-SSS) versus placebo. Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More
News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW. This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer. The top stories: Medication detrimental to gut microbiome,… Read More
The effect of common medication on the gut microbiome could have a detrimental impact on metabolism, the immune system and overall health, a new study reveals. According to a new paper published in Cell Press, researchers at Stanford University, US, found that medications reduce certain bacterial populations and change… Read More
Tim Sharpington, Chief Executive Officer at Microbiotica… Read More
Recent discoveries into gut bacteria and nanomedicines could pave the way for better treatments of gut pain, new research suggests. According to studies published in Cell Host & Microbe and Proceedings of the National Academy of Sciences (PNAS), scientists have discovered a new… Read More
Dr Jeremy Wilkinson, Microbial Genomics Lead, PacBio, explores how genomics are enabling higher-resolution microbiome profiling and highlights four therapeutic areas where this new… Read More
This is the latest episode of the free DDW narrated podcast, titled “How is precision medicine making its mark in drug discovery?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA”… Read More
Scientists have taken an important step toward the development of a potential new treatment for treating Shiga toxin-producing E coli (STEC), the bacteria associated with severe food poisoning. The findings – led by the University of Glasgow and published in Antimicrobials and… Read More
EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class drugs for gut health, has announced positive initial results with EBX-102-02, the company’s next-generation full-spectrum microbiome product, from the TrIuMPH Phase IIa clinical trial in adults with irritable bowel syndrome with constipation (IBS-C). The multicentre, randomised, double-blind, placebo-controlled TrIuMPH (Treating IBS with an… Read More
Microbiotica has revealed new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC). The data were shared at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February in Banff, Canada and at the European… Read More
